Cerity Partners
ONCY icon

Cerity Partners’s Oncolytics Biotech ONCY Stock Holding History

Cerity Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.5K Hold
10,000
– – ﹤0.01% 3392
2026
Q1 		$8.49K Hold
10,000
– – ﹤0.01% 3215
2025
Q4 		$8.74K Hold
10,000
– – ﹤0.01% 2865
2025
Q3 		$14K Hold
10,000
– – ﹤0.01% 2732
2025
Q2 		$7.73K Buy
+10,000
New +$5.3K ﹤0.01% 2623

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Seeds Investor
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Connective Capital Management
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Tocqueville Asset Management
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PFG Investments
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Cerity Partners's ONCY Position: Q2 2026 in Review

Cerity Partners held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 10,000 shares worth $9.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3392.

Cerity Partners first reported a position in ONCY in Q2 2025 and has held it in 5 quarters since. The position peaked at $14K in Q3 2025. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Cerity Partners held 10,000 shares of Oncolytics Biotech worth $9.5K as of Q2 2026.
  • Cerity Partners left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3392 holding.
  • Cerity Partners first reported a position in Oncolytics Biotech in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Oncolytics Biotech position peaked at $14K in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.